Spectral AI, Inc. (Nasdaq: MDAI) has announced its financial results for the first quarter ending March 31, 2025. The company reported a 6.0% increase in Research & Development Revenue, reaching $6.7 million, up from $6.3 million in Q1 2024. Additionally, Spectral AI has improved its capital structure, now holding $14.1 million in cash. The company has also completed a debt financing agreement of up to $15.0 million with Avenue Capital Group, including an initial drawdown of $8.5 million in March 2025. This was complemented by a $2.7 million equity raise from institutional and other investors, aimed at supporting the commercialization of the DeepView System in the U.S. Spectral AI continues to work towards its De Novo submission to the FDA, expected in the first half of 2025. The company reiterated its revenue guidance for FY 2025 at approximately $21.5 million, excluding potential contributions from the upcoming commercialization of the DeepView System.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。